About Us

Pharmakon Advisors, LP is the investment manager of the BioPharma Credit funds. Established in 2009, Pharmakon has raised a total of US$4.2 billion, principally across five private funds and a publicly traded UK Trust. BioPharma Credit PLC (ticker: BPCR.L “BPCR”) was listed on the London Stock Exchange in March 2017 and has raised a total of $1.4 billion in capital. Pharmakon Advisors has committed US$5.5 billion across 43 different financing transactions for companies in the life sciences.

Senior Management

Pedro Gonzalez De Cosio

Pedro Gonzalez de Cosio
Co-Founder, Principal and CEO

Pablo Legorreta

Pablo Legorreta
Co-Founder and Principal

Martin Friedman

Martin Friedman
Principal

Major Transactions

Click on a transaction in order to view the corresponding press release.

January 2022

$300,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-V

December 2021

$125,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-V

March 2021

$300,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-V

February 2020

$200,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-V

December 2019

$250,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-V

December 2019

$550,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-V

November 2019

$100,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-V

November 2019

$220,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-V

September 2019

$150,000,000

Senior Secured Note

Sole Lender

BioPharma PLC & BioPharma-V

May 2019

$80,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC

September 2018

$150,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC

May 2018

$315,000,000

Senior Secured Loan

Lead

BioPharma PLC

February 2018

$150,000,000

Structured Royalty Investment

Sole Lender

BioPharma PLC

December 2017

$150,000,000

Structured Royalty Investment

Marketer

AstraZeneca

Product

Onglyza
Forxiga

Co-Investor

BioPharma PLC

December 2017

$200,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-IV

November 2017

$500,000,000

Senior Secured Loan

Sole Lender

BioPharma PLC & BioPharma-IV

September 2017

$50,000,000

Corporate Loan

Sole Lender

BioPharma-IV

November 2016

Undisclosed

Capped Royalty

Marketer

UCB

Product

Vimpat

Sole Purchaser

BioPharma-IV

January 2016

$150,000,000

Royalty Backed Loan

Marketer

Roche
Baxalta

Product

MabThera SC
Herceptin SC
HyQvia

Lead

BioPharma-IV

December 2015

$175,000,000

Senior Secured Loan

Lead

BioPharma-IV

November 2015

$55,000,000

Senior Secured Loan

Sole Lender

BioPharma-III

March 2015

$575,000,000

Senior Secured Loan

Lead

BioPharma-III

December 2013

$30,000,000

Senior Secured Loan

Marketer

Novartis

Product

Ixiaro

Sole Lender

BioPharma-III

December 2012

$100,000,000

Capped Royalty

Marketer

Amarin

Product

Vascepa

Sole Purchaser

BioPharma-II

November 2012

$30,000,000

Royalty Backed Loan

Marketer

Genentech

Product

Erivedge

Sole Purchaser

BioPharma-II

August 2012

$30,000,000

Capped Royalty

Marketer

Corcept

Product

Korlym

Sole Purchaser

BioPharma-II

August 2012

$78,000,000

Capped Royalty

Marketer

Abbot

Product

Xience

Sole Purchaser

BioPharma-II

June 2010

$100,000,000

Royalty Backed Notes

Marketer

Cubist

Product

Cubicin

Sole Purchaser

BioPharma-I

September 2009

$132,000,000

Royalty Backed Notes

Marketer

Lilly

Product

Cymbalta

Sole Purchaser

BioPharma-I

Press Releases

Latest press releases. Click on a press release to view it in a new window.

Title Company Date
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors Coherus 7 January 2022
Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors Evolus 14 December 2021
LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp LumiraDx 23 March 2021
Collegium Announces Closing of the Nucynta Franchise Acquisition Collegium 13 February 2020
GBT Secures $150 Million Non-Dilutive Term Loan Financing GBT 18 December 2019
Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing Sarepta 13 December 2019
AKEBIA SECURES $100 MILLION NON-DILUTIVE TERM LOAN FINANCING; REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Akebia 12 NOVEMBER 2019
EPIZYME ESTABLISHES AGREEMENTS FOR UP TO $270 MILLION IN FUNDING TO SUPPORT TAZEMETOSTAT COMMERCIALIZATION AMD PIPELINE ADVANCEMENT Epizyme 4 NOVEMBER 2019
Optinose Announces $150 Million Debt Financing from Pharmakon Optinose 12 September 2019
BioDelivery Sciences Strengthens Financial Position with Debt Refinancing BioDelivery Sciences 28 May 2019

Contact

Pharmakon Advisors, LP 110 East 59th Street #3300, New York, NY 10022

T: (212) 883-1006 E: IR@pharmakonadvisors.com

 

The content of this website is provided by the Adviser and offers information about the Adviser and its affiliates and a general overview of its investment program. The content of this website is provided for information purposes only. Nothing on this website shall be construed as an offer to sell or a solicitation of an offer to purchase interests in any private fund managed by the Adviser, nor do they constitute investment advice. The information contained herein is subject to change without notice.

Offers and sales will be made only in accordance with applicable securities laws and pursuant to a confidential private placement memorandum (or similar document) and other fund governing documents, which should be read carefully and in their entirety prior to making an investment. Potential investors should not rely on any of the content of this website in making an investment or other decision but should obtain relevant and specific professional advice.

The content of this website and the investment program which might be referred to therein are not directed at, or intended for, distribution to any person or entity being a citizen or resident of, or located or established in, any jurisdiction where the use of such websites or the sale of such investment programs would be illegal or would require any registration or licensing not held by the Adviser. Such persons or entities access this website at their own risk and must observe any legal or regulatory restrictions which may affect their eligibility to access this website.  The Adviser makes no warranty or guarantee as to the accuracy, completeness or reliability of any information contained on this website. The Adviser shall have no liability for any direct, indirect, consequential or special losses or damages of any kind whatsoever arising from reliance on any of the content of this website.

Loading...